Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
To read the full story
Related Article
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
May 11, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
February 1, 2023
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
- Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
February 1, 2022
- Ono to Decide on Revision of Scholarship Donation Program by Year-End
November 2, 2021
- Ono Enjoys Double-Digit Growth in H1 on Upbeat Opdivo, Forxiga
November 2, 2021
- Ono’s Q1 Sales Up 16.6% on Opdivo Indication Expansions
August 2, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
May 12, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Ono’s Half-Year Operating Profit Up 25.1% on Double-Digit Drop in R&D, SGA Costs Amid COVID-19
October 30, 2020
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
BUSINESS
- Kyowa Kirin Debuts Crysvita Prefilled Syringe and Lumicef Auto-Injector in Japan
November 20, 2025
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
- Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…






